Galderma's Nemluvio Shows Sustained Efficacy in Long-Term Atopic Dermatitis Study
Event summary
- Galderma presented three-year data from the ARCADIA LTE study showing Nemluvio maintained deep and lasting skin lesion and itch responses in atopic dermatitis patients aged 12 and older.
- 76% of early responders achieved clear or almost clear skin (IGA 0/1) and 80% achieved at least a 90% improvement in disease severity (EASI-90) at Week 152.
- Nemluvio was well-tolerated with no new safety signals identified through three years of treatment.
- Additional data supported Nemluvio's potential in pediatric patients (aged 2-11) and prurigo nodularis.
The big picture
Galderma's latest data reinforces Nemluvio's potential as a long-term solution for atopic dermatitis, addressing a significant unmet need in dermatology. The sustained efficacy and safety profile could strengthen Galderma's leadership in the dermatology category, particularly as the company expands into pediatric indications and broader geographic markets. The results come at a time when the dermatology sector is increasingly focused on durable therapies that improve patient quality of life.
What we're watching
- Regulatory Expansion
- Whether Galderma can secure additional regulatory approvals for Nemluvio in pediatric populations and new geographies.
- Market Positioning
- How the sustained efficacy data will position Nemluvio against competitors in the atopic dermatitis and prurigo nodularis markets.
- Commercial Strategy
- The pace at which Galderma can translate long-term clinical data into commercial success and market share growth.